Text Size
17 studies found for:    Open Studies | Vascular Diseases | UCSD OR UC San Diego OR VA San Diego

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY
Conditions: Coronary Artery Disease;   Coronary Arteriosclerosis
Intervention:
2 Recruiting A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
Condition: Coronary Artery Disease
Intervention: Drug: Flurpiridaz F18 Injection
3 Recruiting Prevention of Serious Adverse Events Following Angiography
Conditions: Acute Renal Failure;   Kidney Disease;   Coronary Artery Disease
Interventions: Drug: IV isotonic saline;   Drug: IV isotonic bicarbonate;   Drug: N-acetylcysteine;   Drug: Placebo
4 Recruiting Single Dose Enteral Tranexamic Acid in Critically Ill Patients
Conditions: Shock;   Sepsis;   Hypotension;   Critical Illness
Intervention: Drug: Tranexamic Acid
5 Recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
6 Recruiting Evaluation of the Duration of Therapy for Thrombosis in Children
Condition: Venous Thrombosis
Interventions: Other: Shortened duration (6 weeks) of anticoagulant therapy;   Other: Conventional duration (3 months) of anticoagulant therapy;   Other: No Intervention;   Drug: Dalteparin
7 Recruiting Ventavis® Registry Protocol
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Commercial Ventavis® (iloprost)
8 Recruiting Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Condition: Portopulmonary Hypertension
Intervention: Drug: Ambrisentan
9 Recruiting A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
10 Recruiting A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001
11 Unknown † Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients
Conditions: Chronic Thromboembolic Pulmonary Hypertension;   Acute Lung Injury
Intervention: Other: Ventilation Strategy
12 Recruiting Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Condition: HIV-1 Infection
Intervention: Drug: atorvastatin
13 Recruiting Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: bosentan;   Drug: placebo
14 Recruiting An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Conditions: Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin;   Acute Myeloid Leukemia;   Multiple Myeloma
Intervention: Drug: CAL-101
15 Recruiting Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
16 Unknown † Genetic Study of Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
Conditions: Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
17 Recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Drug: lenalidomide
To Top

† Indicates status has not been verified in more than two years